JonesResearch analyst Debanjana Chatterjee lowered the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $25 and keeps a Buy rating on the shares. The firm updated the company’s model following the fiscal 2025 report. The stock’s recent weakness continues to offer an attractive entry point, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI: